Humanized anti-SIRPα antibodies
AssigneeByondis B.V.
InventorGijsbertus Franciscus Maria Verheijden
Life of this patent
Estimating the term…
Abstract
The present invention relates to humanized antibodies against SIRPα that are suitable for use in anti-cancer therapy. The invention further relates to the use of the humanized anti-SIRPα antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with further anti-cancer therapeutics.
Claims22
A humanized anti-SIRPα antibody or an antigen-binding fragment thereof, comprising heavy chain complementarity determining regions (HCDR) and light chain complementarity determining regions (LCDR) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein the antibody or the antigen-binding fragment thereof comprises:
- a. HCDR1 comprising SEQ ID NO:36;
- b. HCDR2 comprising SEQ ID NO:44;
- c. HCDR3 comprising SEQ ID NO:45;
- d. LCDR1 comprising SEQ ID NO:39;
- e. LCDR2 comprising SEQ ID NO:40;
- and
- f. LCDR3 comprising SEQ ID NO:41.
Dependencies are inferred from the claim text.